Preliminary clinical trial findings: Dexamethasone

In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone.

A total of 2104 patients were randomised to receive dexamethasone 6 mg once per day (either by mouth or by intravenous injection) for ten days and were compared with 4321 patients randomised to usual care alone. Dexamethasone reduced deaths by one-third in ventilated patients and by one fifth in other patients receiving oxygen only. There was no benefit among those patients who did not require respiratory support.

The peer reviewed and published article can be found below.

Preliminary Clinical Trial Findings: Remdesivir

Mark as Understood

Resources

Statement from the Chief Investigators of the RECOVERY Trial on dexamethasone

The RECOVERY Trial

Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report (pre print)

© Institute of Clinical Science and Technology (ICST) 2020

Support: admin@clinicalscience.org.uk